Market Atlas (@MarketAtlasDesk) header
Market Atlas (@MarketAtlasDesk) profile picture

Market Atlas

@MarketAtlasDesk

🇺🇸 US • 🇮🇳 India • 🇨🇦 Canada Equity research • Earnings • Valuation • Markets Independent market research & insights. Not financial advice.

Joined September 2026
  • Tweets1.6K
  • Following39
  • Followers26
150Media
Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)Photo by Market Atlas (@MarketAtlasDesk)
📌 MARKET ATLAS — OUR TRADING RULES We trade the setup. Never our emotions. Here’s how we approach every trade: 🛑 1. MAXIMUM STOP-LOSS: 6% If our stop-loss is hit, we’re out. No averaging down. No excuses. No emotional decisions. (1)
1
682
🧬 $SRRK —Q3 26: ISEMBYLD launch begins as company secures $205M voucher deal #SRRK reported its 1st commercial revenue following FDA approval of ISEMBYLD, its muscle-targeted treatment for spinal muscular atrophy (SMA) The quarter also included important regulatory progress &
1
36
more replies
$SRRK is transitioning from clinical-stage biotech into a commercial-stage company. The $205M voucher transaction should materially strengthen its financial position once completed, while early ISEMBYLD demand is encouraging.
1
16
However, $SRRK commercial revenue remains very small, operating losses are substantial & execution on product launch & international approvals will be critical This remains a high-risk biotech growth story #MarketAtlas #SRRK #ScholarRock #Biotech #Healthcare #Pharma #Earnings
13
📡 $SLAB —Q3 26:Strong IoT demand drives 22% revenue growth & 228% adjusted EPS growth #SLAB delivered strong 3rd quarter,with broad-based growth across Industrial & Commercial & Home & Life markets,while medical revenue reached new record Revenue:$250.9M,up 21.8% YoY vs $206M
1
18
more replies
$SLAB strong quarter, with revenue growth translating into significantly faster adjusted earnings growth. #SLAB medical, industrial & commercial demand are encouraging, while improving inventory conditions could support further growth.
1
8
However, the pending Texas Instruments acquisition means investors should also monitor deal completion & transition rather than relying on standalone forward guidance. #MarketAtlas #SLAB $SLAB #SiliconLabs #Semiconductors #IoT #Earnings #Stocks
16
🔥 $SPB.TO —Q3 26: CNG delivers record EBITDA, but FY outlook downgraded #SPB reported stronger gross profit & adjusted EBITDA, driven by exceptional growth in compressed natural gas (CNG). However, weakness in propane distribution prompted reduction in FY earnings expectations
1
33
more replies
#SPB available revolving credit liquidity was $285.3M Quarterly dividend maintained at C$0.045/share My take on $SPB.TO: #CNG is emerging as meaningful growth engine, with data centre demand providing compelling long-term opportunity
1
16
But propane weakness,customer attrition & higher operating costs are offsetting that momentum Downgrade to FY expectations is reminder that #CNG growth alone cannot yet compensate for weakness in traditional propane business. #MarketAtlas #SPB $SPB.TO #SuperiorPlus #TSX #Energy
9
Load more